Tiagabine Hydrochloride Tablet, Film Coated
Product Images NDC 0093-8076

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tiagabine Hydrochloride (NDC 0093-8076). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 1)

FDA Label Image

Tiagabine Hydrochloride Tablets 2 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 10)

This appears to be a medication label for Tiagabine Hydrochloride tablets, including dosage instructions and the name of the manufacturer (Teva). It also indicates that a medication guide is required and provides a code number for the product.*

FDA Label Image

Tiagabine Hydrochloride Tablets 4 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 11)

FDA Label Image

Tiagabine Hydrochloride Tablets 12 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 12)

FDA Label Image

Tiagabine Hydrochloride Tablets 16 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 13)

FDA Label Image

Figure01 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 2)

This text appears to be a graph depicting the % reduction in partial seizure rate for patients taking Tiagabine HCI 32 + 55 mg/day compared to a placebo. The graph shows a 50% reduction in seizure rate for patients taking Tiagabine, while the placebo group shows no improvement in seizure rate. The graph also includes a scale ranging from -50% to 50%, indicating the degree of improvement or worsening in seizure rate. It appears to be a medical or pharmaceutical study, but without further context, it is difficult to provide a more specific description.*

FDA Label Image

Figure02 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 3)

The text appears to be a chart showing the % reduction in partial seizure rate for patients with different dosages of Tiagabine HCI and a placebo. The chart also shows the % of patients who experienced improvement, no change, or worsening of symptoms.*

FDA Label Image

Figure03 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 4)

The text is a chart that shows the percentage reduction in partial seizure rate for patients taking a placebo versus patients taking Tiagabine HCI at different doses. It also provides the percentage of patients who experienced improvement in seizure rate or no change/worsening.*

FDA Label Image

Figure04 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 5)

The text presents a graph that shows the reduction in partial seizure rate for patients taking a placebo and those taking Tiagabine HCI 10 mg TID. The graph indicates that the reduction in partial seizure rate is 100% for those taking Tiagabine HCI. Therefore, Tiagabine HCI can be considered an effective treatment for partial seizures.*

FDA Label Image

Figure05 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 6)

FDA Label Image

Figure06 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 7)

FDA Label Image

Image07 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 8)

FDA Label Image

Image08 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.